ARA-290

ARA-290, or cibinetide, is an 11-amino-acid peptide derived from a tissue-protective region of erythropoietin (EPO). The original 2017 trial describes its nonerythropoietic research rationale. It is not a 15-amino-acid peptide or the full EPO hormone.

Araim Pharmaceuticals is the developer identified in the cited research, not a chemical synonym. Clinical development and a mechanistic rationale do not establish a general treatment regimen.

The clinical report discusses tissue-repair signaling without the red-cell stimulation sought with conventional EPO treatment. Corneal and skin nerve-fiber measures were used as research endpoints in sarcoidosis-associated small-fiber neuropathy.

A change in a nerve-fiber biomarker is not necessarily a clinically meaningful reduction in pain, and avoiding an intended erythropoietic effect does not establish absence of all EPO-related or other risks.

A 22-patient intravenous pilot found greater improvement on a small-fiber-neuropathy symptom questionnaire, but pain and fatigue improved similarly in active and placebo groups. A 28-patient subcutaneous study reported encouraging corneal and symptom findings.

In the 64-patient randomized 2017 study, 4 mg/day subcutaneous cibinetide for 28 days improved corneal nerve-fiber area relative to placebo: 697 µm² (95% CI 159–1,236; P=0.012). The 1 mg and 8 mg groups did not show that significant primary finding. Patient-reported outcomes were not significantly different between groups; the moderate/severe-pain subgroup’s placebo-corrected 4 mg result was −1.01 (95% CI −2.42 to 0.41; P=0.157).

The 4 mg corneal finding supports further research into small-fiber repair. Skin GAP-43-positive fiber findings also differed from ordinary intraepidermal nerve-fiber density, which did not change significantly.

These are encouraging but specific endpoints. They do not demonstrate uniform pain relief, successful treatment of all neuropathies or durable benefit after stopping; the day-56 between-group corneal comparison was not significant.

The early pilot used 2 mg intravenously three times weekly for four weeks. The 2017 trial instead tested 1, 4 or 8 mg subcutaneously each day for 28 days. These are different trial exposures, not an interchangeable general schedule.

The reviewed sources do not establish a universal personal dose, indefinite maintenance or a predictable approval date. Trial information should not be converted into availability or a treatment recommendation.

The 2017 full report records serious events in two 1 mg recipients judged unrelated to treatment, and suicidal ideation in one 8 mg recipient judged possibly related, leading to withdrawal. This does not prove causation, but it rules out describing the trial as having no serious adverse events.

The short, small studies do not establish long-term safety, absence of immune effects or safe combination with other peptides. The authors disclosed developer-related affiliations and interests.

Original 2012 and 2013 indexed abstracts were read. The original 2017 full paper was obtained and read for methods, nerve outcomes, symptom comparisons and safety; its symptom and adverse-event tables were visually inspected. This is an editorial source review, not a complete current FDA adjudication, clinician sign-off or certification of related guides.